



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,313	01/14/2005	Joon Youb Lee	2298.0080002	9295

26111 7590 01/15/2009
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

EXAMINER

HILL, KEVIN KAI

ART UNIT	PAPER NUMBER
----------	--------------

1633

MAIL DATE	DELIVERY MODE
-----------	---------------

01/15/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/521,313	Applicant(s) LEE ET AL.	
	Examiner KEVIN K. HILL	Art Unit 1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 November 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 29-37, 44, 45, 47, 48 and 61-77 is/are pending in the application.
- 4a) Of the above claim(s) 31 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 29, 30, 32-37, 44, 45, 47, 48 and 61-77 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>September 22, 2008</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1633

Detailed Action ***Election/Restrictions***

Applicant has elected without traverse the Her-2/neu plasmid construct species “a”, a Her2/neu plasmid construct, wherein the human Her-2/neu gene has the nucleotide sequence of SEQ ID NO:2, and the cytokine species “GM-CSF”.

Amendments

In the reply filed November 20, 2008, Applicant has cancelled claims 1-28, 38-43, 46 and 49-60, withdrawn claim 31, amended claims 29-37, 44-45 and 47, and entered new claims 61-77.

Claim 31 is pending but withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a non-elected invention, there being no allowable generic or linking claim.

Claims 29-30, 32-37, 44-45, 47-48 and 61-77 are under consideration.

Response to Declaration

1. **The Kang Declaration under 37 CFR 1.132 filed September 22, 2008 is acknowledged and has been considered.**

Exhibit	Antigen	Mammalian Subject	Prevention	Treatment	GM-CSF	tumor challenge	pre-existing tumor
AB	CEA	mouse, healthy	no	yes**	no	yes ^h	no
AC	CEA	human, cancer	no	no	no	no	yes ^{AA}
AD	beta-galactosidase	mouse, healthy, BALB/c	no	yes**	no	yes ^h	no
AE	IgG-interleukin fusion	mouse, healthy, BALB/c	no	yes**	no	no	yes ^{AA}
AF	plasmodium	human, healthy	no	no	no	no	no
AG	HIV antigen	human, healthy	no	no	no	no	no
AH	HIV antigen	chimpanzee, healthy	no	no	no	no	no
AI	not Her2/neu	general review article	no				
AJ	rabies glycoprotein	monkeys, healthy	no	no	no	no	no
AK	HIV infection	general review article	no	no	no		
AL*	not Her2/neu	general review article	no	yes**	yes***		
AM	tetanus-Fv fusion	mouse, healthy	no	yes**	no	yes ^h	no
AN*	HIV antigen	human, healthy	no	no	no	no	no
AO*	Ebola virus antigen	human, healthy	no	no	no	no	no
AP*	Her2/neu	general review article	no	yes**	yes***		
AQ*	Her2/neu	human, cancer	no	no	no	no	no

Applicant argues that:

a) the use of mice injected with cancer cells is a commonly used preclinical model for testing cancer vaccines, including protein and DNA vaccines, as shown by the following articles published prior to the effective priority date of the present application (¶7);

Art Unit: 1633

b) as of the priority date of the current invention, the animal model used to test the DNA vaccine of the current invention was commonly used in the art in preclinical studies of vaccines, and was viewed as reasonably predictive of similar results in mammals, including humans (§6, §8);

c) as of the priority date of the current invention, persons of ordinary skill in the art would consider the induction of CTL and antibody responses in the animal model used in the current invention a reasonable indicator of anti-tumor immunity in humans (§9), as it was known that induction of anti-tumor immunity, in part, involves CTL responses; and

d) as of the time of filing, several studies had shown that antibody and CTL responses in mice could be recapitulated in other mammals, including humans (§10).

Applicant's arguments and Exhibits have been fully considered, but are not persuasive.

With respect to a-d), the art recognizes that the rodent models are useful to establish the principles of Her-2/neu targeted therapy (AP, 2008, pg 3, col. 2, §3), but such models are insufficient for the real world human application. Rather, "With the available immune modulating tools to complement vaccination, there is optimism that Her-2 vaccine will become a reality." (AP, pg 5, col. 2, Concluding Remarks). "Critical information will be revealed in the next decade to expedite the development of cancer vaccines" (AP; pg 1, col. 2). As discussed below, the specification does not disclose how to practice the inventive methods and use the inventive compositions to overcome immune tolerance, avoid autoimmune disease, yet achieve a real world, clinically meaningful prevention and/or therapeutic treatment of Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung in humans. Neither the prior art nor the instant specification discloses a nexus between the objective and quantifiable degree of antibody response and/or CTL induction achieved in animal models, e.g. rodent, and the objective and quantifiable degree of antibody response and/or CTL induction necessary to achieve the prevention and/or treatment of said genus of tumors in humans.

Regarding the Exhibits(*), AL, AN, AO, AP and AQ are post-filing publications. These references were published after Applicants' effective filing date. The state of the art is what one

Art Unit: 1633

skilled in the art would have known, at the time the application was filed, about the subject matter to which the claimed invention pertains. The relative skill of those in the art refers to the skill of those in the art in relation to the subject matter to which the claimed invention pertains at the time the application was filed. The specification must be enabling as of the filing date, not evidence provided several years after the date of filing. The state of the art for a given technology is not static in time. It is entirely possible that a disclosure filed on January 2, 1990, would not have been enabled. However, if the same disclosure had been filed on January 2, 1996, it might have enabled the claims. Therefore, the state of the prior art must be evaluated for each application based on its filing date. (see MPEP §2164.05(a)). In the instant case, the exhibits (references) provided by Applicants do not establish enablement of the claimed invention at the time of filing.

Regarding the Antigen, only Exhibits AE, AP and AQ address the Her-2/neu antigen. However, AE teaches Her2/neu antibody-interleukin chimeric gene therapy, not DNA vaccination therapy. None of the Exhibits teach a predictable nexus between the immune response profile and therapeutic efficacy of a first antigen, e.g. CEA, β -galactosidase, etc..., as it pertains to the instantly claimed Her2/neu antigen for the prevention and treatment of breast cancer at the time of the invention. Antigen immunogenicity between a first antigen and a second antigen is difficult to predictably correlate because the steps involved in antigen processing and the kinetics of antigen presentation may differ between antigens (AN; pg 7, ¶1).

Regarding the Mammalian subject, as discussed in the rejection under 35 U.S.C. first paragraph, enablement, the major drawback to the use of plasmid DNA vaccines in humans is that, although proven to be quite effective in rodents, DNA-based vaccines have generally performed poorly in both non-human primate studies as well as in human clinical trials. The art recognizes that FVB and BALB/c mice used for testing experimental DNA vaccines may not be representative for the human scenario (Chang et al; *of record). In the case of human Her-2/neu in human patients, the artisan may not reasonably extrapolate the ability to breakdown tolerance and induce an effective immune response, as achieved in animal models, because Her-2/neu is a self-tolerated antigen widely expressed at low levels in multiple tissues in humans. None of the

Art Unit: 1633

exhibits (pre- and post-filing) provide the necessary information to overcome said obstacle. Neither AH nor AJ teach a nexus that establishes a predictable treatment outcome between HIV or rabies vaccination for the treatment or prevention of pathogen infection and the instant claims regarding the prevention and treatment of breast cancer. The Examiner notes that both AL and AP teach that "the major limitation to using self-tumor antigens for cancer vaccine is that they are protected by self-tolerance mechanisms. This is largely a scientific question, one that should be answered in the affirmative before asking the medical question of whether cancer vaccines can induce meaningful clinical benefit. Since tolerance to tumor associated antigen is profound, strenuous immune modulation is required to achieve a meaningful response. (AP; pg 1, col. 1) In the case of one antigen, Id, it has taken 10 years to answer this question in a definitive manner. (AL; pgs 1-2, joining ¶) "Critical information will be revealed in the next decade to expedite the development of cancer vaccines" (AP; pg 1, col. 2).

Regarding Prevention, none of the Exhibits demonstrate a real world prevention of disease. Preventing cancer is even less predictable than treatment because one would have to predict a person who is going to develop the cancer based on genetic background, which is at its infancy, in addition to factoring in the gene and environment interaction. The specification is devoid of any models or experimental analysis that reasonably suggests that the claimed medicine would predictably prevent Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung in a real world subject, specifically humans. This, combined with the state of the art, suggests that undue experimentation would be required to practice the invention as broadly claimed. Further studies are needed to determine the optimal *preventive* [emphasis added] gene-based vaccine strategy (AO; pg 1276, col. 1, ¶3).

Regarding Treatment (), Tumor Challenge(^) and Pre-existing Tumor(^ ^)**, AB assays tumor challenge, not *in vivo* tumor development as it would occur in a human patient; and thus does not address treatment of pre-existing tumor. Furthermore, the tumor challenge assay is only documented for a short-term (42 days). AD assay tumor challenge to vaccinated mice, whereupon the analysis is performed only three days post challenge. In a pre-existing tumor

Art Unit: 1633

model, AD administered tumor cells two days prior to treatment with heterologous splenocytes, not a vaccination regimen of host animal. Thus, the splenocytes were already selected for antibody expression, and thus the experiment does not address growing tumor burden concomitant with immunization. AE assay the effect of pre-existing tumor cells, administered only one day prior to treatment, only 15 days after treatment. No therapeutic efficacy of anti-Her2/neu antibody alone is taught, nor a vaccination regimen of host animal. The relatively short assay windows, 3 days, 15 days, 42 days, etc., do not adequately represent a real world application for a clinically meaningful therapeutic treatment because those of ordinary skill in the art, and especially those cancer patients in need of treatment, recognize that cancer treatment occurs over many months and years.

AC teaches a clinical trial designed for safety and toxicity evaluation. AC teaches no evidence of prevention, but rather that most patients continued with progressive disease. AC acknowledges the importance of promoter selection to achieve necessary antigen expression level, as well as the low frequency of response due to patient immune-compromised status.

AM teaches a 130 day experiment regarding the efficacy of an antigen-antibody gene fusion directed against a tumor challenge. However, there is no teaching of a nexus between the tetanus toxin-Fv gene fusion and the efficacy of a Her-2/neu vaccination regimen for the treatment of Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung.

AP summarizes experimental protocols to develop Her-2/neu DNA vaccines in animal models, but is not commensurate in scope to the claimed invention which embraces humans.

The efficacy of DNA vaccine against tumor progression suffer several drawbacks, for example, immunization of healthy animals against a subsequent challenge with tumor cells was assayed rather than treatment of a tumor-bearing animal with DNA vaccine. However, patients with established, rapidly growing tumors can have an impaired cellular and humoral immune system. Therefore, it might be difficult to activate immunological defense mechanisms by vaccination. The immunogenicity of the DNA vaccine reflects a combination of factors, including optimization of vector design, manufacturing methods, delivery, sample processing and immunological end-point measurements (AN; pg 6, ¶5).

Art Unit: 1633

Regarding GM-CSF (*)**, while AL teaches that GM-CSF has been used in combination with a DNA vaccine in experimental models for Non-Hodgkin's lymphoma (NHL), AL does not teach a nexus between the treatment regimen of NHL and the treatment of Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung. AP briefly mentions initial trials combining GM-CSF with Her-2/neu DNA vaccines; however, the results of such trials are published after the filing date of the instant application. No predictable nexus is taught regarding the therapeutic efficacy of an interleukin (AD, AE) and GM-CSF.

The benefit of co-administration of cytokine genes is dependent on the nature of tumor-associated antigen and the intrinsic immunologic properties of tumor cells. The existence of multiple immune regulatory pathways necessitates systematic evaluation of therapeutic approaches in clinical trials to determine the optimal combination immunotherapy regimen (AL; pg 7, col. 2, last sentence).

Priority

This application is a 371 of PCT/KR03/01400, filed July 15, 2003, and claims priority to KR 10-2002-0041764, filed July 15, 2002 and KR 10-2003-0038012, filed June 12, 2003.

Acknowledgment is made of Applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d).

In the response filed July 17, 2007, Applicant has submitted a certified translation of Korean Patent Application No. 10-2002-0041764, filed July 16, 2002 and Korean Patent Application No. 10-2003-0038012, filed June 12, 2003.

Accordingly, the effective priority date of the instant application is granted as July 16, 2002.

Information Disclosure Statement

Applicant has filed Information Disclosure Statements on September 22, 2008 that has been considered. The signed and initialed PTO Form 1449 is mailed with this action.

Examiner's Note

Unless otherwise indicated, previous objections/rejections that have been rendered moot in view of the amendment will not be reiterated. The arguments in the November 20, 2008 response will be addressed to the extent that they apply to current rejection(s).

Claim Objections

2. **The prior objection to Claim 29 is withdrawn** in light of Applicant's amendment to the claim.

Claim Rejections - 35 USC § 112

3. **The prior rejection of Claims 47-60 under 35 U.S.C. 112, second paragraph, is withdrawn** in light of Applicant's amendment to the claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. **The prior rejection of Claims 49-60 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is withdrawn** in light of Applicant's cancellation of the claims.
5. **Claims 47-48 stand and Claims 61, 64-65 and 71-77 are newly rejected under 35 U.S.C. 112, first paragraph**, because the specification, while being enabling for methods of preventing, treating and reducing a Her-2/neu-over-expressing cancer in a rodent, and the method(s) comprising the step of administering by intramuscular injection an effective amount of a DNA vaccine composition comprising i) a pTV2 or pCK plasmid construct comprising a promoter operably linked to a nucleotide sequence encoding a C-terminally truncated human Her-2/neu protein, said protein consisting of a signal peptide, the entire extracellular domain and transmembrane domain of Her-2/neu or a signal peptide and the entire extracellular domain of Her-2/neu, and ii) and adjuvant, and wherein said DNA vaccine composition further comprises a nucleic acid encoding the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), does not reasonably provide enablement for a method of preventing, treating or reducing a Her-2/neu over-expressing cancer in humans. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

Art Unit: 1633

This rejection is applied to the newly added claims, yet is essentially the same argument set forth in the prior Office Actions and is maintained for reasons of record, re-stated below. This rejection is maintained for reasons of record in the Office Action mailed April 22, 2008 and re-stated below. The rejection has been re-worded slightly based upon Applicant's amendment filed November 20, 2008.

While determining whether a specification is enabling, one considers whether the claimed invention provides sufficient guidance to make and use the claimed invention. If not, whether an artisan would have required undue experimentation to make and use the claimed invention and whether working examples have been provided. When determining whether a specification meets the enablement requirements, some of the factors that need to be analyzed are: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill, the level of predictability in the art, the amount of direction provided by the inventor, the existence of working examples, and whether the quantity of any necessary experimentation to make or use the invention based on the content of the disclosure is "undue" (*In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)). Furthermore, USPTO does not have laboratory facilities to test if an invention will function as claimed when working examples are not disclosed in the specification. Therefore, enablement issues are raised and discussed based on the state of knowledge pertinent to an art at the time of the invention. And thus, skepticism raised in the enablement rejections are those raised in the art by artisans of expertise.

The Breadth of the Claims and The Nature of the Invention

With respect to the DNA vaccine composition, the breadth of the claim is exceptionally large for encompassing a genus of structurally distinct nucleic acid compositions encoding structurally and biologically distinct polypeptides for use as a DNA vaccine for the treatment and/or prevention of Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung.

When the claims are analyzed in light of the specification, the inventive concept of the instant application is to provide a DNA vaccine composition for preventing or treating cancer, wherein the specification discloses that Her-2/neu is amplified and over-expressed in several types of human adenocarcinomas, especially tumors of the breast and ovary. Thus, the Her-2/neu oncogene is an excellent target for the development of therapeutic vaccines specific for Her-2/neu-over-expressing human cancers (pg 1, lines 15-28).

The State of the Prior Art, The Level of One of Ordinary Skill and The Level of Predictability in the Art

Her-2/neu is an oncogene coding for a transmembrane protein (p185neu) and belonging to the family of tyrosine kinase growth factor receptors. Her-2/neu gene amplification and consequent over expression of Her-2/neu receptor have been observed in a significant proportion of human cancers including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung and is intimately associated with malignant phenotype and aggressiveness of the malignancy. The relevant art of the instant invention is DNA vaccines, wherein the level of skill for an ordinary artisan is high.

Art Unit: 1633

DNA Vaccine

At the time of the instant application (priority date of July, 2002), limited data was available regarding DNA vaccination in humans. In the early trials, eliciting anti-tumor immunity in cancer patients using DNA vaccines has proved more difficult, and little evidence of anti-tumor immunity was demonstrated using first generation tumor antigen DNA vaccines.

DNA vaccine model represents a promising, practical and effective way to elicit immune responses against an antigen expressed by malignant cells. An issue in developing tumor DNA vaccines is to design protocols that can be translated from murine models to large animal models and clinical human use without losing their potency (Smorlesi et al, Vaccine 24: 1766-1775, 2006, pg 1767, col. 1, ¶1). The quality of the immune response elicited by a DNA vaccine is also dependent by the procedure of DNA delivery that influences the mechanisms of DNA uptake, transgene expression, and transgene product processing. The results of tumor antigen DNA vaccine approaches might be improved by optimization of key variables such as dosage, route, vector design, and boosting strategies. Thus, the role of the DNA delivery system on the outcome of the vaccine should be considered in the elaboration of a HER2/*neu* DNA vaccine.

The efficacy of DNA vaccine against HER2/*neu* is influenced by the method of release of DNA. Smorlesi et al showed that vaccine delivery methods, e.g. intramuscular injection, electroporation, and gene gun, elicited diverse immune mechanisms that differently prevented the appearance and the development of spontaneous mammary carcinomas (Smorlesi et al; pg 1773, col. 1, ¶1). The art also recognizes that the non-obvious use of a particular promoter for required expression in the desired cell type. For example, SV40, although a relatively strong promoter in fibroblasts and epithelial cell types, may be weaker than the commonly used cytomegalovirus promoter. (Chen et al, Clinical Cancer Research 6: 4381-4388, 2000; pg 4385, col. 2).

Many of the experimental systems used to evaluate the efficacy of DNA vaccine against tumor progression suffer several drawbacks, for example, immunization of healthy animals against a subsequent challenge with tumor cells was assayed rather than treatment of a tumor-bearing animal with DNA vaccine. However, patients with established, rapidly growing tumors can have an impaired cellular and humoral immune system. Therefore, it might be difficult to activate immunological defense mechanisms by vaccination (Bernhard et al, Society for Endocrinology 9(1): 33-44, 2002; pg 40, col. 1, ¶1). Moreover, while the amount of produced antibodies only partially correlate with the outcome of vaccination, the quality of humoral response seems to be determinant for the success of vaccination. Immunized mice can develop anti-Her-2/*neu* antibody, as demonstrated by Western blotting, but are provided no protection from tumor progression (Chen et al; pg 4385, col. 2, lines 15-17). Therefore, it is likely that DNA vaccine against a specific tumor-associated antigen may not be sufficient by itself to prevent progression of native pre-existing tumor.

The art also recognizes that a number of concerns exist with respect to immunizing with Her-2/*neu* vaccines. For example, once concern is that the polyclonal humoral response generated may contain immunoglobulins that can activate the Her-2/*neu* receptor, as has been found with some monoclonal antibodies, and lead to increased cell growth rather than inhibition (Esserman et al, Cancer Immunol. Immunother. 47: 337-342, 1999; pg 340, col. 2, ¶3). Furthermore, it is possible that increasing the anti-Her-2/*neu* immunity to a level necessary to

Art Unit: 1633

destroy cancer tissue *in vivo* may also increase levels of autoimmune reactivity against normal tissues to the point of inducing toxicity (Esserman et al; pg 341, col. 1, lines 17-21).

Animal models

Most DNA vaccine investigations are performed in models of implanted tumors that consist of the challenge of mice with a bolus of tumor cells giving rise to a fast and unnaturally growing tumor. Furthermore, the roles of p185Her-2/neu on tumor growth and immunomodulation may be altered in tumors over-expressing rat or human p185Her-2/neu. The therapeutic response may thus depend on the type of vaccine administered as well as the cancer cells used in the animal study (Lin et al, Molecular Therapy 10(2): 290-301, 2004; pg 296, col. 1, lines 11-14). Therefore, the efficacy of Her-2/neu DNA vaccine must be tested on mouse tumor cells natively over-expressing mouse p185Her-2/neu (Lin et al, pg 291, col. 1, ¶1). The art recognizes that transgenic mice reproduce the more complex spontaneous progression of a pre-neoplastic lesion and their use provides information that may be more relevant to cancer development in humans where the tumor is initiated by the clonal expansion from a single cell *in vivo* (Smorlesi et al; pg 1767, col.s 1-2, joining ¶). For example, the *Her-2/neu* transgenic mice possess distinct kinetics of disease development that better reflect spontaneous mammary carcinogenesis and recapitulate a few features of the development of human mammary carcinoma.

Although the results using plasmid DNA vaccines against HER2 have been promising in rodent models, there are drawbacks when considering the use of plasmid DNA vaccines in humans. The major drawback to the use of plasmid DNA vaccines in humans is that, although proven to be quite effective in rodents, DNA-based vaccines have generally performed poorly in both non-human primate studies as well as in human clinical trials. Thus, until formulation and delivery technologies are developed to increase the potency of plasmid DNA vaccines in humans, this approach is not likely to be an optimal one for human vaccines (Foy et al, Seminars in Oncology 29(3 Suppl. 11): 53-61, 2002; pg 56, col. 2, ¶1). Furthermore, the art recognizes that FVB and BALB/c mice used for testing experimental DNA vaccines may not be representative for the human scenario (Chang et al, Int. J. Cancer 111: 86-95, 2004; pg 86, col. 1, last sentence). In the case of human Her-2/neu in human patients, the artisan may not reasonably extrapolate the ability to breakdown tolerance and induce an effective immune response, as achieved in animal models, because Her-2/neu is a self-tolerated antigen widely expressed at low levels in multiple tissues in humans.

Cytokine therapy

Cytokine genes have been used in many studies to enhance the immune response to a DNA vaccine against a specific antigen. Fusion genes or co-delivery of cytokine genes can augment the immune response and influence the immune pathway. The anti-tumor responses induced by different cytokines seemed to operate through different mechanisms. For example, cytotoxic CD8⁺ T cells play a major role in the IL-2-induced immune response, whereas CD4⁺ and CD8⁺ T cells mediate the GM-CSF anti-tumor activity (Chen et al; pg 4381, col. 2, ¶1). Although several studies have indicated that GM-CSF had a strong capacity to enhance the effects of DNA vaccines by amplifying both cellular and humoral immunity, the benefit of co-

Art Unit: 1633

administration of cytokine genes is dependent on the nature of tumor-associated antigen and the intrinsic immunologic properties of tumor cells (Lin et al; pg 298, col. 1, ¶1).

Thus, the art recognizes significant unpredictability regarding the design of any Her-2/neu DNA vaccine, with or without combined administration of nucleic acids encoding a cytokine, to reliably prevent or treat an enormous genus of etiologically and pathologically distinct tumors in an enormous genus of mammalian organisms, including mice and humans. The art speaks to the lack of standards in animal models, the difficulties to adequately mimic the complex disease pathologies observed in humans to the animal model system, and the general inability to reliably extrapolate results achieved in the rodent system to the primate system.

The Existence of Working Examples and The Amount of Direction Provided by the Inventor

The specification teaches the tumor challenge in laboratory BALB/c mice by injection of suspended human breast carcinoma cells or murine colon adenocarcinoma cells (pg 13, lines 1-5), wherein said cells either administered subcutaneously on the flank or intravenously (pg 15, lines 29-30). Applicant contemplates an enormous genus of DNA vaccine formulations and administration means (pgs 9-10); however, only intramuscular injection is disclosed as an effective administration means of vaccination. The specification also does not teach the structural nature of the expression plasmids; merely disclosing that the pCK vector has a stronger promoter activity than pTV2 (pg 22, line 18). Furthermore, the claims reasonably embrace a pTV2Neu_{TM}-GMCSF bi-cistronic expression plasmid, yet no such plasmid is disclosed in the specification. The inventive DNA vaccines are administered either before or after the tumor challenge by intramuscular injection. Under experimentally controlled conditions, the vaccinated mice were able to generate antibodies to the Her-2/neu antigen (Example 3), suppress tumor challenge, exhibit decreased frequency of tumor metastasis, and prolonged survival periods (Examples 4-6).

The specification fails to disclose that the inventive method is capable of achieving the clinically desirable results as per spontaneous tumor formation, which is the clinically relevant condition, in any other mammal, including primates such as humans. Such guidance is important in light of the wealth of data in the art teaching the inability to predictably extrapolate the instant rodent model to humans.

The Quantity of Any Necessary Experimentation to Make or Use the Invention

Thus, the quantity of necessary experimentation to make or use the invention as claimed, based upon what is known in the art and what has been disclosed in the specification, will create an undue burden for a person of ordinary skill in the art to demonstrate that the instantly claimed DNA vaccine compositions can prevent or treat an enormous genus of etiologically and pathologically distinct cancers, as contemplated by Applicant and reasonably embraced by the claims, via the enormous genus of contemplated composition formulations and administration means because the critical and essential elements of the DNA vaccine expression plasmids are not disclosed so as to guide an artisan how to make the DNA vaccine compositions and effectively target the nucleic acid to the desired cell types so as to effect the immunological response. Furthermore, the art recognizes that the model system disclosed, wherein a bolus of tumor cells is administered to the host, does not adequately represent the clinical condition

Art Unit: 1633

wherein a patient has any one of an enormous genus of genotypically and phenotypically distinct cancers in any one of a multitude of physiologically and pathologically distinct organs and tissues.

In conclusion, the specification fails to provide any guidance as to how an artisan would have dealt with the art-recognized limitations of the claimed method commensurate with the scope of the claimed invention and therefore, limiting the claimed invention to methods of preventing and treating a Her-2/neu-over-expressing cancer in a rodent, the method(s) comprising the step of administering by intramuscular injection an effective amount of a DNA vaccine composition comprising a pTV2 vector or pCK vector which comprises a nucleotide sequence encoding a truncated human Her-2/neu protein, said truncated human Her-2/neu protein lacking an intracellular domain, and wherein said DNA vaccine composition further comprises a nucleic acid encoding the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), is proper.

Response to Arguments

Applicant argues that:

a) Applicants herein provide evidence to support that one skilled in the art would be able to make and use the full scope of the claimed invention using the application as a guide, without undue experimentation. Applicants respectfully point out that such evidence need not be conclusive but merely convincing to one of skill in the art. See M.P.E.P. §2164.05;

b) Applicants contend that the animal model example in the specification constitutes a working example that "correlates" with a disclosed or claimed method of the invention, i.e. is reasonably predictive of similar results in mammals, including humans;

c) Applicant again asserts that inoperative embodiments are permissible; and

d) as evidenced by clinical trials currently in progress, the quantity of any necessary experimentation to make or use the invention is not unreasonable.

Applicant's argument(s) has been fully considered, but is not persuasive.

With respect to a), Applicant has provided no evidence that one of ordinary skill in the art would find the Exhibits presented nor the instant specification sufficient to be *convinced* [emphasis added] that the instant invention may be practiced to *prevent* [emphasis added] Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung.

With respect to b), as discussed in the rejection and response above, the art recognizes that the major drawback to the use of plasmid DNA vaccines in humans is that, although proven

Art Unit: 1633

to be quite effective in rodents, DNA-based vaccines have generally performed poorly in both non-human primate studies as well as in human clinical trials. The art recognizes that FVB and BALB/c mice used for testing experimental DNA vaccines may not be representative for the human scenario. In the case of human Her-2/neu in human patients, the artisan may not reasonably extrapolate the ability to breakdown tolerance and induce an effective immune response, as achieved in animal models, because Her-2/neu is a self-tolerated antigen widely expressed at low levels in multiple tissues in humans. None of the exhibits (pre- and post-filing) provide the necessary information to overcome said obstacle. The Examiner notes that both AL and AP teach that "the major limitation to using self-tumor antigens for cancer vaccine is that they are protected by self-tolerance mechanisms. This is largely a scientific question, one that should be answered in the affirmative before asking the medical question of whether cancer vaccines can induce meaningful clinical benefit. Since tolerance to tumor associated antigen is profound, strenuous immune modulation is required to achieve a meaningful response. (AP; pg 1, col. 1) In the case of one antigen, Id, it has taken 10 years to answer this question in a definitive manner. (AL; pgs 1-2, joining ¶) The art recognizes that the rodent models are useful to establish the principles of Her-2/neu targeted therapy (AP, 2008, pg 3, col. 2, ¶3), but such models are insufficient for the real world human application. Rather, "With the available immune modulating tools to complement vaccination, there is optimism that Her-2 vaccine will become a reality." (AP, pg 5, col. 2, Concluding Remarks). "Critical information will be revealed in the next decade to expedite the development of cancer vaccines" (AP; pg 1, col. 2).

With respect to c), the claims embrace a real-world use of the invention of significant economic and medical impact, namely treatment of humans suffering from Her-2/neu-over-expressing cancers. Thus, the inoperative embodiment, specifically prevention and treatment of humans, is a real-world consideration and fundamental flaw within the scope of the invention that is not enabled by the instant specification.

With respect to d), AP and AQ are post-filing publications. These references were published after Applicants' effective filing date. The state of the art is what one skilled in the art would have known, at the time the application was filed, about the subject matter to which the claimed invention pertains. The relative skill of those in the art refers to the skill of those in the art in relation to the subject matter to which the claimed invention pertains at the time the

Art Unit: 1633

application was filed. The specification must be enabling as of the filing date, not evidence provided several years after the date of filing. The state of the art for a given technology is not static in time. It is entirely possible that a disclosure filed on January 2, 1990, would not have been enabled. However, if the same disclosure had been filed on January 2, 1996, it might have enabled the claims. Therefore, the state of the prior art must be evaluated for each application based on its filing date. (see MPEP §2164.05(a)). In the instant case, the exhibits (references) provided by Applicants do not establish enablement of the claimed invention at the time of filing.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the Examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the Examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. **Claims 29-30, 32-37, 44-45, 47-48 stand and Claims 61-77 are newly rejected under 35 U.S.C. 103(a)** as being unpatentable over Piechocki et al (J. Immunol. 167: 3367-3374, 2001) in view of Erickson et al (WO 01/00244), Lee et al (J. Virol. 72(10):8430-8436, 1998), Lee et al (Biochem. Biophys. Res. Comm. 272(1): 230-235, 2000) and Chen et al (Cancer Res. 58:1965-1971, 1998; *of record in IDS).

Art Unit: 1633

This rejection is maintained for reasons of record in the Office Action mailed April 22, 2008 and re-stated below. The rejection has been re-worded slightly based upon Applicant's amendment filed November 20, 2008.

Determining the scope and contents of the prior art.

With respect to the claimed plasmid expression constructs, Piechocki et al teach a plasmid DNA vaccine comprising a nucleotide sequence encoding a truncated human Her-2/neu polypeptide, said polypeptide consisting of an extracellular domain, specifically the amino terminal amino acids 1-505 of the mature human Her-2/neu extracellular domain (pg 3368, col. 1, Construction).

Piechocki et al teach that vaccination with secE2 (a signal peptide and the entire extracellular domain of Her-2/neu) induced ErbB-2-specific antibodies, protected ~90% of mice against mammary tumors, induced a CTL response, and was comparable with that of wildtype ErbB-2 encoding the entire Her-2/neu protein (Abstract). SecE2 conferred similar protection as full-length Her-2/neu. The DNA vaccine was administered intramuscularly in to skeletal muscles (pg 3369, col. 1, ¶1).

Piechocki et al do not teach the use of the entire extracellular domain of mature Her-2/neu (amino acids 1-652), nor the use of an adjuvant with the DNA vaccine. However, at the time of the invention, Chen et al taught the ability of the ordinary artisan to express sub-domains of Her-2/neu, specifically the extracellular domain (pNeu_E) or the extracellular and transmembrane domains (pNeu_{TM}). Chen et al teach this basic skill in molecular biology applied to rat Her-2/neu; however, the sequence and structure of human Her-2/neu was known at the time and it was/is well within the skill of the ordinary artisan to apply such designed protein subdivision towards human Her-2/neu. Chen et al teach the administration of an adjuvant such as GM-CSF (pg 4382, col. 2; pg 4383, Figure 1).

Neither Piechocki et al nor Chen et al teach the truncated human Her-2/neu polypeptide to be encoded by a nucleic acid sequence comprising SEQ ID NO:2. However, Erickson et al is but one example demonstrating that the sequence of human Her-2/neu having 100% identity to SEQ ID NO:2 was known in the art prior to the instant invention (see attached Search Result for SEQ ID NO:2).

Neither Piechocki et al, Chen et al nor Erickson et al teach the use of a pTV2 vector. However, at the time of the invention, Lee et al (1998) taught the eukaryotic expression vector

Art Unit: 1633

pTV2 used to express a single gene of interest, specifically GM-CSF, E1t or E2t, or as bi-cistronic expression plasmid to express a gene of interest in combination with GM-CSF [an adjuvant], wherein the gene of interest and GM-CSF are separated by an internal ribosome entry site (IRES) (pg 8430, col. 2, Construction; pg 8431, Figure 1). Lee et al teach a pharmaceutical composition comprising either the bi-cistronic pTV2 vector comprising GM-CSF or a first pTV2 plasmid encoding a gene of interest in combination with a second pTV2 plasmid encoding GM-CSF, and a carrier, specifically sterile saline administered to rats in an experiment to ascertain if said vector is capable of immunization (pg 8432, col. 2; Table 1).

Neither Piechocki et al, Chen et al, Erickson et al nor Lee et al (1998) teach a pCK vector. However, at the time of the invention, Lee et al (2000) taught the construction of a pCK expression plasmid that is able to drive high levels of gene expression *in vivo* for therapeutic use. Lee et al teach the use of this vector to express VEGF165 in mice when administered in combination with a pharmaceutical carrier, e.g. PBS, as an example of gene therapy (pg 231, col. 1, Animal Model; pg 233, Figure 5).

With respect to the claimed methods, Piechocki et al teach a method of preventing or treating cancer and inducing anti-tumor immunity, reducing tumor growth and prolonging survival period in a mammal, the method comprising administering an effective amount of a pharmaceutical composition comprising an expression vector encoding a truncated human Her-2/neu polypeptide, said polypeptide consisting of the extracellular domain of mature Her-2/neu to laboratory BALB/c mice who received three intramuscular injections of DNA vaccine prior to challenge with Her-2+ D2F2 murine mammary tumor cells over-expressing Her-2/neu (pg 3369, col. 1, Inhibition of Tumor Growth; pg 3371, Figure 3), as measured by CTL response (pg 3372, Figure 5) and production of anti-Her-2/neu-specific antibodies (pg 3370, col. 2). Piechocki et al teach that all tumor-free mice at 10 weeks after tumor challenge were capable of rejecting a second tumor challenge, demonstrating sustained immunity to tumor-associated antigens (pg 3370, col. 2, lines 1-8).

Ascertaining the differences between the prior art and the claims at issue, and Resolving the level of ordinary skill in the pertinent art.

People of the ordinary skill in the art will be highly educated individuals such as medical doctors, scientists, or engineers possessing advanced degrees, including M.D.'s and Ph.D.'s. Thus, these people most likely will be knowledgeable and well-read in the relevant literature and have the practical experience in molecular biology and DNA vaccine immunization methods. Therefore, the level of ordinary skill in this art is high.

Piechocki et al do not teach the tumor cells to be ovarian cancer. However, nothing non-obvious is seen with substituting breast cancer cells with ovary cancer cells because the art recognizes that both breast and ovary cancer cells overexpress Her-2/neu (Piechocki et al, pg 3367, col. 1, ¶1). Thus, the method of inducing antitumor immunity and prolonging survival period of breast cancer via the use of a Her-2/neu DNA vaccine would also be capable of inducing antitumor immunity and prolonging survival period of ovary cancer, absent evidence to the contrary, as the claims recite the breast and ovary cancers as alternatives (and thus essentially equivalent) and there is nothing in the instant disclosure to clearly distinguish method steps

Art Unit: 1633

designed specifically for treating breast cancer from method steps designed specifically for treating ovary cancer.

Piechocki et al do not explicitly teach a method of decreasing tumor metastasis as per the use of the human Her-2/neu DNA vaccine. However, absent evidence to the contrary, the capability to decrease tumor metastasis would naturally flow from the DNA vaccine and the method steps performed by Piechocki et al that demonstrated prevention and treatment of cancer, induction of antitumor immunity, reduced tumor growth and prolonged survival periods were also sufficient to decrease tumor metastasis because the DNA vaccine is the same and there is no patentable distinction in the method step by which the vaccine is administered to the subject so as to clearly exclude the clinically effective method of decreasing tumor metastasis from the methods of preventing or treating cancer, inducing antitumor immunity, reducing tumor growth and prolonging survival periods.

The Examiner notes that the pCK vector of Lee et al (2000) is deposited at the KCCM under the Accession No. KCCM-10179 (specification; pg 16, lines 11-12). Thus, the pCK vector of Lee et al (2000) comprising a transmembrane and extracellular domain of human Her-2/neu encoded by SEQ ID NO:2 (Piechocki et al, Erickson et al and Chen et al) would be structurally indistinguishable from pCK_{TM} deposited at the KCCM under the Accession No. KCCM-10396, absent evidence to the contrary. Similarly, the pTV2 vector of Lee et al (1998) comprising a transmembrane and extracellular domain of human Her-2/neu would be structurally indistinguishable from pTV2_{TM} deposited at the KCCM under the Accession No. KCCM-10393, absent evidence to the contrary.

The Examiner notes that the substitution of E1t or E2t for a transmembrane and extracellular domain of human Her-2/neu encoded by SEQ ID NO:2 (Piechocki et al, Erickson et al and Chen et al) into the pTV2 bi-cistronic expression plasmid comprising a GM-CSF gene (Lee et al, 1998) would be structurally indistinguishable from pCK_{TM}-GMCSF recited in claim 37.

Considering objective evidence present in the application indicating obviousness or nonobviousness.

It would have been obvious to one of ordinary skill in the art to substitute the expression vector of Piechocki et al with the pTV2 or pCK expression vectors as taught by Lee et al (1998 and 2000) with a reasonable chance of success because the simple substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Lee et al (1998 and 2000) teach the ability of such vectors for use as *in vivo* DNA delivery vehicles, e.g. DNA vaccines. Furthermore, nothing non-obvious is seen with replacing one expression vector for another expression vector because the Her-2/neu gene is under the same regulatory control, specifically the CMV promoter, in the pTV2 vector as is also present in the pCK vector, and thus the substitution of a pCK vector for a pTV2 vector would yield predictable results as the vectors are functionally equivalent. An artisan would be motivated to use the expression vectors of Lee et al (1998 and 2000) because Lee et al teach that, for example, the newly developed pCK vector efficiently expressed the exogenously added gene *in vivo*, and reproducibly produced much higher levels of the target polypeptide than all expression vectors tested so far, including commercially available HCMV IE promoter-based plasmids and those using housekeeping gene promoters. Furthermore, Lee et al suggest that pCK

Art Unit: 1633

provides clear advantages over other previously developed plasmids, and would not only significantly increase therapeutic effects at a given dose, but also lower the costs of production, and thus treatment. With respect to the broad applicability for *in vivo* gene therapy, Lee et al anticipate the vector should be useful for gene therapy for any disease that can be treated with a reasonable level of gene expression in a transient manner in a localized area (pg 234, Discussion). Similarly, Lee et al (1998) teach that co-delivery of GM-CSF gene using the pTV2 expression vector elicited higher lymphoproliferative responses to a gene of interest than without GM-CSF. Co-delivery of the GM-CSF gene enhances T-helper cell responses in DNA-based immunization (pg 8434, col.s 1-2).

It also would have been obvious to one of ordinary skill in the art to try substituting the Her-2/neu extracellular domain of Piechocki et al for the entire extracellular domain of Her-2/neu because the simple substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention and “a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipate success, it is likely that product not of innovation but of ordinary skill and common sense.” An artisan would be motivated to try substituting the Her-2/neu extracellular domain of Piechocki et al for the entire extracellular domain of Her-2/neu because the extracellular domain of Piechocki et al is missing ca.147 amino acids which would likely provide additional antigenic peptide motifs and/or improve the immunization response to the DNA vaccine.

It also would have been obvious to one of ordinary skill in the art to try using a pTV2 or pCK expression vector encoding a truncated human Her-2/neu polypeptide, said polypeptide consisting of an extracellular domain or the transmembrane and extracellular domains of the mature human Her-2/neu extracellular domain in methods of preventing or treating cancer, inducing anti-tumor immunity, reducing tumor growth, decreasing tumor metastasis and prolonging survival in a human subject suffering from a Her-2/neu-over-expressing human cancer because “a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipate success, it is likely that product not of innovation but of ordinary skill and common sense.” An artisan would be motivated to try using a pTV2 or pCK expression vector encoding a truncated human Her-2/neu polypeptide, said polypeptide consisting of of an extracellular domain or the transmembrane and extracellular domains of the mature human Her-2/neu extracellular domain in methods of preventing or treating cancer, inducing anti-tumor immunity, reducing tumor growth, decreasing tumor metastasis and prolonging survival in a human subject suffering from a Her-2/neu-over-expressing human cancer because ErbB-2 has long been recognized as a target of immunotherapy in that several human cancers, including breast, ovarian, and lung cancers overexpress ErbB-2, which is associated with aggressive disease and poor prognosis (Piechocki et al, pg 3367, col. 1, Introduction).

Thus, the invention as a whole is *prima facie* obvious.

Response to Arguments

Applicant argues that:

Art Unit: 1633

a) the Piechocki construct does not contain the *entire* extracellular domain, nor does it include the *entire* extracellular domain and transmembrane domain;

b) the current specification discloses properties of the pharmaceutical compositions of the current invention that were unpredictably superior to the secE2 construct disclosed in Piechocki;

c) Piechocki teaches away from use of a pharmaceutical composition comprising a C-terminally truncated Her-2/neu construct, without presentation of the other Her-2/neu epitopes, for prevention or treatment of cancer as described in the claimed invention because Piechocki predicts that co-vaccination with DNA encoding *all* Her-2/neu epitopes is needed to achieve elevated CTL activity and complete tumor protection. In contrast, the current specification shows that the DNA vaccine of the claimed invention achieved CTL induction and complete tumor protection, as well as inhibition of tumor growth after injection, without all epitopes of Her-2/neu;

d) Chen teaches a rat Her-2/neu extracellular domain, not the human Her-2/neu. The human Her-2/neu nucleotide and amino acid sequences are different than the rat Her-2/neu nucleotide and amino acid sequences.

e) Erickson does not describe the exact nucleotide sequence of SEQ ID NO:2 of the current invention. Instead, Erickson discloses the full length Her-2/neu sequence.

f) Chen in combination with Lee 1 and/or Lee 2 is structurally distinguishable from pCK_{TM}, pTV2_{TM} and pCK_{TM}-GMCSF, contrary to the Examiner's assertion.

g) Applicants assert that the plasmid construct of the invention was not predictable in view of the cited references, especially due to the numerous potential vectors that could be envisioned and a lack of disclosure to support selection of the pTV2 or pCK vectors for expression of the C-terminally truncated Her-2/neu gene of the current invention;

h) at the time of Applicants' invention, it was *unknown* which Her-2/neu epitopes were likely to provide the best tumor rejection in animal models and humans; and

i) the disclosure of the human Her-2/neu C-terminally truncated construct of the claimed invention in combination with an adjuvant that induces antibody and CTL responses, and is effective in both preventative and therapeutic models, is an improvement over the Her-2/neu constructs cited by the examiner.

Applicant's argument(s) has been fully considered, but is not persuasive.

With respect to a-b), in response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In the instant case, it is the combination of Piechocki et al, Erickson et al, Lee et al (1998), Lee et al (2000) and Chen et al that render the instant claims *prima facie* obvious.

With respect to c), Applicant appears to have overlooked that Piechocki et al teach that vaccination with secE2 induced ErbB-2-specific antibodies, protected ~90% of mice against mammary tumors, induced a CTL response, and was comparable with that of wildtype ErbB-2 encoding the entire Her-2/neu protein. SecE2 conferred similar protection as full-length Her-2/neu (Abstract; Figure 3). While a greater effect is achieved via combination therapy, Piechocki et al do not necessarily and absolutely teach away from the instant invention.

With respect to d-e), in response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In the instant case, Chen et al teach the scientific concept that the mammalian Her-2/neu extracellular domain alone may be tested in DNA vaccine formulations, and yield protective effect (see pg 1968, Figure 6). Applicant has provided no evidence of record that the ordinary artisan would be incapable of designing and expressing a truncated human Her-2/neu protein for a DNA vaccine as per the successfully demonstrated teachings of Chen et al using the rat Her-2/neu extracellular domain. Chen et al teach this basic skill in molecular biology applied to rat Her-2/neu; however, the sequence and structure of human Her-2/neu was known in the art prior to the invention (Erickson), the functional domains of Her-2/neu were known in the prior art, and the ordinary artisan would know where to truncate a full-length sequence to obtain a nucleic acid sequence encoding only the domain(s) of interest, e.g. only the extracellular domain or the extracellular domain and transmembrane domain, as per the teachings of Chen.

With respect to f), Applicant is respectfully reminded that it is the combination of Piechocki et al, Erickson et al, Lee et al (1998), Lee et al (2000) and Chen et al that render the instant claims *prima facie* obvious. Applicant appears to have overlooked the teachings of Erickson.

Art Unit: 1633

With respect to g), it is unclear what feature renders the plasmid construct(s) unpredictable. It is well known that it is *prima facie* obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to form a third composition which is useful for the same purpose (as well as to use such a composition for that purpose - i.e., expressing a heterologous protein in a DNA vaccine). The idea for combining them flows logically from their having been used individually in the prior art, and from them being recognized in the prior art as useful for the same purpose. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients. *In re Kerkhoven*, 626 F.2d 846, 850, 205 U.S.P.Q. 1069 (CCpA 1980), *In re Sussman*, 1943 C.D. 518; *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423,426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960). The rationale to modify or combine the prior art does not have to be expressly stated in the prior art; the rationale may be expressly or impliedly contained in the prior art or it may be reasoned from knowledge generally available to one of ordinary skill in the art, established scientific principles, or legal precedent established by prior case law. *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988); *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992); *In re Nilssen*, 851 F.2d 1401, 1403, 7 USPQ2d 1500, 1502 (Fed. Cir. 1988) (references do not have to explicitly suggest combining teachings); and *Ex parte Levengood*, 28 USPQ2d 1300 (Bd. Pat. App. & Inter. 1993) (reliance on logic and sound scientific reasoning). MPEP §2144 In the instant case, the Her-2/neu extracellular domain, both rodent and human (Chen, Piechocki, Erickson), were used to formulate DNA vaccines, and Lee et al (1998, 2000) teach that the pCK and pTV2 expression vectors achieve high levels of expression of a heterologous protein in skeletal muscle, which is the tissue routinely used in the art to induce an antibody response via DNA vaccines. Thus, the each of the prior art elements were known and used for their known purpose. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

Art Unit: 1633

With respect to h-i), neither the claims nor the specification disclose which epitopes are both necessary and sufficient to achieve the “best tumor rejection”. The term 'epitope' refers to the minimal structural unit of an antigen, e.g. specific amino acid peptide sequence that triggers a corresponding antibody response (see www.google.com/search?hl=en&defl=en&q=define:epitope&sa=X&oi=glossary_definition&ct=title, last visited January 7, 2009). Applicant has provided no evidence for which specific epitope(s) of human Her-2/neu, alone and in combination with an adjuvant, induces antibody and CTL responses to achieve a real world and clinically meaningful prevention and treatment of Her-2/neu-over-expressing cancers, including carcinoma of the breast, prostate, ovary, uterus, stomach and adenocarcinoma of the lung in humans, as required by the claims. Applicant's invention (and argument) is predicated on an unexpected result, which typically involves synergism, an unpredictable phenomenon highly dependent upon specific proportions and/or amounts of particular ingredients. Accordingly, the instant claims, the combination of structural elements, i.e. Her-2/neu extracellular domain, pCK or pTV2 expression vector, intramuscular injection, and a GM-CSF adjuvant, where no unexpected results are observed, would have been obvious to one of ordinary skill having the above cited references before him/her. The adjustment of particular conventional working conditions (e.g., determining appropriate amounts of such ingredients therein) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

Conclusion

7. No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1633

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Kevin K. Hill, Ph.D. whose telephone number is 571-272-8036. The Examiner can normally be reached on Monday through Friday, between 9:00am-6:00pm EST.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Joseph T. Woitach can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kevin K. Hill/

Examiner, Art Unit 1633

/Q. JANICE LI, M.D./

Primary Examiner, Art Unit 1633